Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation

6 Feb 2017

Abstract excerpt

// Satoshi Fujii 1 , Satoshi Yamashita 2 , Takeshi Yamaguchi 3 , Masato Takahashi 4 , Yasuo Hozumi 5 , Toshikazu Ushijima 2 , Hirofumi Mukai 6 1 Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan 2 Division of Epigenomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, 104-0045, Japan 3 Department of Medical Oncology,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Treatment and Pharmacology
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28186977
DOI: 10.18632/oncotarget.15118

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylationPMID 28186977Read ↗

Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapySemantic proximity Read ↗

Identification and validation of a novel prognostic signature with DNA methylation-driven genes for survival prediction of breast cancerSemantic proximity Read ↗

Breast cancer biomarkers and molecular medicine.Semantic proximity Read ↗

DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Semantic proximity Read ↗

Detection of biomarkers related to the diagnosis and prognosis of breast cancer through the combination of gene expression profiling and DNA methylationSemantic proximity Read ↗

Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted TherapiesSemantic proximity Read ↗

The Role of Methylation in Breast Cancer Susceptibility and Treatment.Semantic proximity Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.Semantic proximity Read ↗

DNA Methylation Based Molecular Subtypes Predict Prognosis in Breast Cancer PatientsSemantic proximity Read ↗

Epigenetic reprogramming in breast cancer: from new targets to new therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.